IMPACT OF THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (ACCORDING TO THE RENAISSANCE REGISTER)
https://doi.org/10.14412/1995-4484-2019-421-425
Abstract
Objective: to assess changes in health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE) during performed therapy.
Subjects and methods. The investigation included 128 patients with reliable SLE who fulfilled the 2012 SLICC criteria. Sixty-eight patients received standard therapy; 60 used biological agents (BA). During the first visit and at 12 months, all the patients were assessed for disease activity using by SLEDAI-2K and for organ damage employing the SLICC damage index (DI). HRQoL was assessed by the LupusQoL questionnaire that was filled out by the patients independently.
Results and discussion. At Visit 1, the disease activity index averaged 8.0±7.3 in the standard therapy group and 15.4±7.6 in the BA group (p≤0.001); DI was 1.2±0.9 and 1.8±1.8, respectively (p=0.008). BA-treated patients had significantly lower HRQoL scores on all questionnaire scales, except «dependence on others» and «emotional health» ones Both the standard therapy and BA groups showed significantly lower disease activity during Visit 2 at 12 months. HRQoL assessment revealed significant improvements in the scales «pain», «planning», «intimate relationships», «emotional health», «body image», and «fatigue» in the BA group. The standard therapy group had a statistically significant improvement in the scale «dependence on others». All the other scales of the questionnaire displayed a positive change in HRQoL; however, it did not reach statistical significance.
About the Authors
L. D. Vorobyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
S. K. Solovyev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
G. M. Koilubaeva
Academician M. Mirrakhimov National Center for Cardiology and Therapy
Kyrgyzstan
3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan
Kyrgyzstan
3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan
S. I. Glukhova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913-9.
2. Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-target SLE recommendations from the International Task Force and Russian experts’ commentaries. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):9-16 (In Russ.). doi: 10.14412/1995-4484-2015-9-16
3. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266-71. doi: 10.1093/rheumatology/ken479
4. Fernandez-Nebro A, de la Fuente J, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMA B study. Lupus. 2012;21(10):1063-76. doi: 10.1177/0961203312446627
5. Kumar K, Gordon C, Barry R, et al. ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837-44. doi: 10.1177/0961203311398512
6. Gamble R, Dellavalle R. A randomized controlled trial of belimumab for the treatment of active systemic lupus erythematosus. Arch Dermatol. 2012;148(3):376-8. doi: 10.1001/archdermatol.2011.1266
7. Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309
8. Calvo-Alen J, Silva-Fernandez L, Ucar-Angulo E, et al. SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin. 2013;9(5):281-96. doi: 10.1016/j.reuma.2013.04.001
9. Furie R, Petri MA, Strand V, et al. Clinical, laboratory and health related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: A post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1:e000031. doi: 10.1136/lupus-2014-000031
10. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: Results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(10 suppl. 1). doi: 10.1177/0961203312465781
11. Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. Lupus. 2016;25:1111-21. doi: 10.1177/0961203316652494
12. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139
13. Novik AA, Ionova TI, Kaind P. In: Kontseptsiya issledovaniya kachestva zhizni v meditsine [The concept of the study of quality of life in medicine]. St. Petersburg: Elbi; 1999. 140 p. (In Russ.).
14. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913-9.
15. McElhone K, Abbott J, Teh L-S. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10). doi: 10.1177/0961203306071710
16. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266-71. doi: 10.1093/rheumatology/ken479
17. Furie R, Cash J, Cronin M, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001;28:257-65.
18. Kumar K, Gordon C, Barry R, et al. ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus. 2011;20(8):837-44. doi: 10.1177/0961203311398512
19. Polderman M, Huizinga T, Le-Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind placebo controlled crossover trial. Ann Rheum Dis. 2001;60:112-5. doi: 10.1136/ard.60.2.112
20. Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309
21. Dobkin PL, DaCosta D, Joseph L, et al. Counterbalancing patient demands with evidence: results from a pan-Canadian randomised clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med. 2002;24:88-99. doi: 10.1207/S15324796ABM2402_05
22. Furie R, Petri MA, Strand V, et al. Clinical, laboratory and health related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: A post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1:e000031. doi: 10.1136/lupus-2014-000031
23. Strand V, Aranow C, Cardiel M, et al. Improvement of healthrelated quality of life in SLE patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003;12:677-86. doi: 10.1191/0961203303lu440oa
24. Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics. Lupus. 2016;25:1111-21. doi: 10.1177/0961203316652494
25. Karlson E, Liang M, Eaton H, et al. A randomised clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:1832-41. doi: 10.1002/art.20279
26. Novik AA, Ionova TI, Kaind P. In: Kontseptsiya issledovaniya kachestva zhizni v meditsine [The concept of the study of quality of life in medicine]. St. Petersburg: Elbi; 1999. 140 p. (In Russ.).
27. Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosterone
28. McElhone K, Abbott J, Teh L-S. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10). doi: 10.1177/0961203306071710
29. supplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550
30. Furie R, Cash J, Cronin M, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol. 2001;28:257-65.
31. Schinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oa
32. Polderman M, Huizinga T, Le-Cessie S, Pavel S. UVA-1 cold light treatment of SLE: a double blind placebo controlled crossover trial. Ann Rheum Dis. 2001;60:112-5. doi: 10.1136/ard.60.2.112
33. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233
34. Dobkin PL, DaCosta D, Joseph L, et al. Counterbalancing patient demands with evidence: results from a pan-Canadian randomised clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med. 2002;24:88-99. doi: 10.1207/S15324796ABM2402_05
35. Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865
36. Strand V, Aranow C, Cardiel M, et al. Improvement of healthrelated quality of life in SLE patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003;12:677-86. doi: 10.1191/0961203303lu440oa
37. Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718
38. Karlson E, Liang M, Eaton H, et al. A randomised clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:1832-41. doi: 10.1002/art.20279
39. Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062
40. Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosterone
41. Tse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xx
42. supplement on health related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity. 2005;38:531-40. doi: 10.1080/08916930500285550
43. Grootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776
44. Schinffenbauer J, Simon LS. Randomised controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus. 2004;13:398-405. doi: 10.1191/0961203303lu1033oa
45. Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828
46. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233
47. Thumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.
48. Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73:838-44. doi: 10.1136/annrheumdis-2012-202865
49. Rood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.
50. Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res. 2019 Jun;71(6):811-21. doi: 10.1002/acr.23718
51. Elera-Fitzcarrald C, Magaly A, Gamboa-Cardenas R, et al. Factors associated with HRQoL in Peruvian patients with SLE. Lupus. 2018;0:1-7. doi: 10.1177/0961203317751062
52. Tse K, Tang C, Lio W, et al. Quality of life comparison between corticosteroidand- mycofenolate mofetil and corticosteroidandoral cyclophosphamide in the treatment of severe lupus nephritis. Lupus. 2006;5:371-9. doi: 10.1191/0961203306lu2307xx
53. Grootscholten C, Ligtenberg G, Derksen R. Health-related quality of life in patients with systemic lupus erythematosus: Development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12:635-44. doi: 10.1023/A:1025176407776
54. Dussan K, Magder L, Brodsky R. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008;17:1079-85. doi: 10.1177/0961203308093828
55. Thumboo J, Fong K, Chan S, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000;27:1414-20.
56. Rood M, Borggreve S, Huizinga T. Sensitivity to change of the MOS SF-36 quality of life assessment questionnaire in patients with systemic lupus erythematosus taking immunosuppressive therapy. J Rheumatol. 2000;27:2057-8.
Review
For citations:
Vorobyeva L.D., Aseeva E.A., Solovyev S.K., Koilubaeva G.M., Glukhova S.I. IMPACT OF THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (ACCORDING TO THE RENAISSANCE REGISTER). Rheumatology Science and Practice. 2019;57(4):421-425. (In Russ.) https://doi.org/10.14412/1995-4484-2019-421-425
Views:
717
Email this article 